Project: Development of potent therapeutic bispecific antibodies that enhance tumor immunity

Combine the proprietary technologies of the consortium members to develop one or more bispecific antibodies that specifically target and positively modulate anti-tumor immunity. The project will deliver: > 1 lead bispecific antibody with a pre-clinical proof of concept and research cell bank ready for manufacturing; > 1 antibody screening assay based on unresponsive human T cells that mimics the phenotype of T cells present in the human tumor microenvironment ready for commercialization.

Acronym	iMOD-ReACT (Reference Number: 10599)
Duration	15/08/2016 - 01/08/2018
Project Topic	Biological Sciences / Technologies
Network	Eurostars 2
Call	Eurostars Cut-Off 5

Project partner

Number	Name	Role	Country
24624	Merus BV	Coordinator	Netherlands
24625	Aquila BioMedical Ltd	Partner	United Kingdom